Literature DB >> 24276082

Bladder cancer: Progress in defining progression in NMIBC.

Michael Gierth1, Maximilian Burger.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24276082     DOI： 10.1038/nrurol.2013.270

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Bladder cancer: Gaps in staging and care identified.

Authors:  Mina Razzak
Journal:  Nat Rev Urol       Date:  2013-08-20       Impact factor: 14.432

2.  Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series.

Authors:  Simone Bertz; Stefan Denzinger; Wolfgang Otto; Wolf F Wieland; Robert Stoehr; Ferdinand Hofstaedter; Arndt Hartmann
Journal:  Histopathology       Date:  2011-10       Impact factor: 5.087

Review 3.  Bladder cancer in 2012: Challenging current paradigms.

Authors:  Aidan P Noon; James W F Catto
Journal:  Nat Rev Urol       Date:  2013-01-08       Impact factor: 14.432

Review 4.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

Authors:  Marko Babjuk; Maximilian Burger; Richard Zigeuner; Shahrokh F Shariat; Bas W G van Rhijn; Eva Compérat; Richard J Sylvester; Eero Kaasinen; Andreas Böhle; Joan Palou Redorta; Morgan Rouprêt
Journal:  Eur Urol       Date:  2013-06-12       Impact factor: 20.096

5.  Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.

Authors:  Simone Bertz; Wolfgang Otto; Stefan Denzinger; Wolf F Wieland; Maximilian Burger; Robert Stöhr; Stefan Link; Ferdinand Hofstädter; Arndt Hartmann
Journal:  Eur Urol       Date:  2012-05-19       Impact factor: 20.096

Review 6.  Histologic grading of noninvasive papillary urothelial neoplasms.

Authors:  Gregory T MacLennan; Ziya Kirkali; Liang Cheng
Journal:  Eur Urol       Date:  2006-10-27       Impact factor: 20.096

7.  Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients.

Authors:  Stefan Denzinger; Wolfgang Otto; Hans-Martin Fritsche; Wolfgang Roessler; Wolf F Wieland; Arndt Hartmann; Maximilian Burger
Journal:  Int J Urol       Date:  2007-11       Impact factor: 3.369

8.  Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.

Authors:  Maximilian Burger; Madelon N M van der Aa; Johanna M M van Oers; Anke Brinkmann; Theodorus H van der Kwast; Ewout C Steyerberg; Robert Stoehr; Wim J Kirkels; Stefan Denzinger; Peter J Wild; Wolf F Wieland; Ferdinand Hofstaedter; Arndt Hartmann; Ellen C Zwarthoff
Journal:  Eur Urol       Date:  2007-12-26       Impact factor: 20.096

Review 9.  Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy.

Authors:  Bas W G van Rhijn; Maximilian Burger; Yair Lotan; Eduardo Solsona; Christian G Stief; Richard J Sylvester; J Alfred Witjes; Alexandre R Zlotta
Journal:  Eur Urol       Date:  2009-06-26       Impact factor: 20.096

Review 10.  Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition.

Authors:  Donald Lamm; Raj Persad; Maurizio Brausi; Roger Buckley; J Alfred Witjes; Joan Palou; Andreas Böhle; Ashish M Kamat; Marc Colombel; Mark Soloway
Journal:  J Urol       Date:  2013-08-22       Impact factor: 7.450
  10 in total
  4 in total

1.  Tissue Permeability Effects Associated with the Use of Mucoadhesive Cationic Nanoformulations of Docetaxel in the Bladder.

Authors:  Rakhi Pandey; John K Jackson; Clement Mugabe; Richard Liggins; Helen M Burt
Journal:  Pharm Res       Date:  2016-04-18       Impact factor: 4.200

2.  A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.

Authors:  Mónica Martínez-Fernández; Marta Dueñas; Andrew Feber; Cristina Segovia; Ramón García-Escudero; Carolina Rubio; Fernando F López-Calderón; Claudio Díaz-García; Felipe Villacampa; José Duarte; María J Gómez-Rodriguez; Daniel Castellano; José L Rodriguez-Peralto; Federico de la Rosa; Stephan Beck; Jesús M Paramio
Journal:  Oncotarget       Date:  2015-12-08

3.  Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis.

Authors:  Feng Chen; Tao Huang; Yu Ren; Junjun Wei; Zhongguan Lou; Xue Wang; Xiaoxiao Fan; Yirun Chen; Guobin Weng; Xuping Yao
Journal:  BMC Urol       Date:  2016-08-30       Impact factor: 2.264

4.  Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer.

Authors:  Ying-Li Lin; Yan-Ling Wang; Xing-Li Fu; Wen-Ping Li; Yu-Hao Wang; Jian-Guo Ma
Journal:  Oncotarget       Date:  2016-05-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.